Cap cost sharing for prescription insulin drugs, diabetes devices

HB 263 proposes to limit the out-of-pocket costs for individuals needing essential diabetes treatments. The bill specifically aims to cap cost-sharing for prescription insulin drugs, diabetes devices, and devices used to treat diabetic ketoacidosis. If enacted, it would establish a new section in the Revised Code to enforce these caps, reducing the financial burden on patients who rely on these medical necessities.